| Literature DB >> 21220609 |
Guido Marcucci1, Torsten Haferlach, Hartmut Döhner.
Abstract
Molecular analyses of leukemic blasts from patients with acute myeloid leukemia (AML) have revealed a striking heterogeneity with regard to the presence of acquired gene mutations and changes in gene and microRNA expression. Multiple submicroscopic genetic alterations with prognostic significance have been discovered. Application of gene- and microRNA profiling has identified genome-wide expression signatures that separate cytogenetic and molecular subsets of patients with AML into previously unrecognized biologic and/or prognostic subgroups. These and similar future findings are likely to have a major impact on the clinical management of AML because many of the identified genetic alterations not only represent independent prognosticators, but also may constitute targets for specific therapeutic intervention. In this report, we review genetic findings in AML and discuss their clinical implications.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21220609 DOI: 10.1200/JCO.2010.30.2554
Source DB: PubMed Journal: J Clin Oncol ISSN: 0732-183X Impact factor: 44.544